Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with or without bempegaldesleukin versus cystectomy alone in cisplatin-ineligible muscle-invasive bladder cancer
NL-OMON55385Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in bladder cancer and transitional cell carcinoma (TCC) comparing Nivolumab + bempegaldesleukin, Nivolumab monotherapy and Standard of care (3 arms). Primary endpoints: Pathologic complete response rate and Event-free survival. Started Oct 2020; status: completed.
02
Drugs
nivolumabbempegaldesleukin
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON55385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55385.